TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Remission at the 6-month follow-up visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: capacity to participate in an exercise programme
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intensity of aerobic exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitral-valve area improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: New York Heart Association functional class I
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Action tendencies towards neutral stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for rescue with antiemetic
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative drop-out rate
Endpoint domain: Adverse events/effects
Primary endpoint: Job placement rates
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Weeks employed per job
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Hourly wages earned
Endpoint domain: Life impact
Endpoint subdomain: Economic functioning
Primary endpoint: mean antibiotic-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrent infections
Endpoint domain: Adverse events/effects
Primary endpoint: muscular electrical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serving of fruits/vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serving of sugar-sweetened beverages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serving of sugar-sweetened foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Probiotic supplement usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Central augmentation index (AI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systemic arterial compliance (SAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Baseline plasma citrulline levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waist circumference improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weekly minutes of moderate physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until rescue medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Barthel Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Albumin elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Amount of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall Success Rate (SFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: final 28 days abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total spine aBMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee flexion strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Plasma vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma B12 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Standardised FEV(1)AUC(22‐24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Objective and subjective efficacy measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk for death, MI, or rehospitalization for ACS
Endpoint domain: Mortality/survival
Primary endpoint: Norepinephrine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Overall Response Rate (OIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBC/platelet independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced Vital Capacity (FVC) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Borg score for perceived exertion
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Systemic inflammation parameters (fibrinogen and CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oxidative stress (OS) parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prosody improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracer material clearance from the duodenum into the jejunum at 4 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of tracer change between hour 1 and 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: overall redness of the face
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: telangiectasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin texture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Initiation of sexual intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Improvement in functional abilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial expressions associated with myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of PCMO
Endpoint domain: Adverse events/effects
Primary endpoint: therapeutic results on solar lentigines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: prevention of postiatrogenic hyperpigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Bone remodelling balance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of formation markers (PINP and OC(1-49))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biofilm coverage area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median AUC of amlodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median AUC of diltiazem
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Desacetyldiltiazem AUC increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of unprotected vaginal sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Increase in median peak VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LLDAS attainment at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak V̇O2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visceral adipose tissue area decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Astigmatism reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General quality of life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency of major symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular (LV) systolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endocervical pro-inflammatory cytokine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvements in SNA angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in ANB angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in overjet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in molar relationship
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recruitment accrual rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Lower dose of rescue analgesic (fentanyl) required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Longer pain-free period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urethral stricture recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triglyceride response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean terminal elimination half-life (t1/2,z)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No convulsions during the study period
Endpoint domain: Adverse events/effects
Primary endpoint: Healing of nonsevere ulcers at 21 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diastolic dysfunction severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systemic recurrences
Endpoint domain: Mortality/survival
Primary endpoint: Total SPPB score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chair-stand component
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 400 m walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average adjusted symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in sedation (ESS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Reduction in alcohol craving (PACS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blood glucose-lowering effects of repaglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin-elevating effects of repaglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetics of repaglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AVP (Aqueous Humor Dynamics)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive rate of RT‐PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Positive rate of RIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: mean estradiol (E2) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean progesterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean luteinizing hormone (LH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: HIV-1 RNA undetectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-gp41 antibody titre
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-1 DNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VMA resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastrointestinal temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Thermal comfort (TC)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Reduction in mutans count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PAC-SYM scores for opioid-induced constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Resistance to fracture under simulated occlusal load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of peribulbar block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of ≥4 points in RASS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced relapse risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge gains of parents
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient satisfaction with point-of-care testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Confidence in the collection process
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Agreement with statements relating to satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean survival over 6 months
Endpoint domain: Mortality/survival
Primary endpoint: incremental cost per life-year saved (LYS)
Endpoint domain: Resource use
Primary endpoint: Bleeding for more than two weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Time taken for procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: improvement in hippocampal memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Acute exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: pulsatile LH secretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Wakings per night
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Intra- and interrater reliability of shoulder movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of severity of oral mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of management of oral mucositis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: postconcussive symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consonant articulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vowel space recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total IPSS change at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PVR change at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of responders to SSRIs or COCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: beta2-microglobulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary oxalate excretion relative to creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Admission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average airway cross-sectional area increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 3-month effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom improvement rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Laxative use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma B12 bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disability-free survival at day 90
Endpoint domain: Mortality/survival
Primary endpoint: knowledge about mammography
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: overall reduction in mortality due to screening mammography
Endpoint domain: Mortality/survival
Primary endpoint: proportions of women who required follow‐up mammograms
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: fecal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: MCC time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of screening for colorectal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective signs of withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of labial adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to tumor progression (TTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Apparent oral bioavailability of docetaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thrombin-antithrombin complexes levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: soluble tissue factor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: plasminogen activator inhibitor type I activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of responders
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Social phobia rating scales
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Measures of psychosocial disability
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Prevalence of histopathologically confirmed placental malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of symptomatic malaria during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of composite adverse birth outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Rate of access site conversions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: In situ free blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endothelial damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Use of hemostatic clips
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Relapsing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median VAS with IUD insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Thrombosis-free patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: motor function in the lower limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aqueous flare intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operatively induced astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean scores on the knowledge test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean anteroposterior renal pelvic diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: split renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Ovarian hyperstimulation syndrome (OHSS) rates
Endpoint domain: Adverse events/effects
Primary endpoint: Serum BSAP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality risk associated with GDF-15
Endpoint domain: Mortality/survival
Primary endpoint: Combined endpoint of CV death or hospitalization for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Heart failure death risk associated with GDF-15
Endpoint domain: Mortality/survival
Primary endpoint: global lumbar angular ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall level of attractiveness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lung function measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Nighttime awakenings
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Percentage of patients alive without disease progression at 30 months
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients with a complete response or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diarrhoea duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain VAS scores
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: FACIT-F scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Normalized alanine aminotransferase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes